Mereo BioPharma Group Gestione
Gestione criteri di controllo 4/4
Mereo BioPharma Group's CEO is Denise Scots-Knight, appointed in Jul 2015, has a tenure of 9.33 years. total yearly compensation is $2.22M, comprised of 25.5% salary and 74.5% bonuses, including company stock and options. directly owns 1.92% of the company’s shares, worth $12.59M. The average tenure of the management team and the board of directors is 6.7 years and 3.6 years respectively.
Informazioni chiave
Denise Scots-Knight
Amministratore delegato
US$2.2m
Compenso totale
| Percentuale dello stipendio del CEO | 25.5% |
| Mandato del CEO | 9.3yrs |
| Proprietà del CEO | 1.9% |
| Durata media del management | 6.7yrs |
| Durata media del Consiglio di amministrazione | 3.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Is Mereo BioPharma Group (NASDAQ:MREO) Weighed On By Its Debt Load?
Apr 07
Is Mereo BioPharma Group (NASDAQ:MREO) Using Debt Sensibly?
Nov 25Mereo stock rises 12% on FDA fast-track status for lung disease drug alvelestat
Oct 17Rubric Capital boosts Mereo BioPharma board nominees slate to five
Oct 03Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside
Sep 22Mereo activist investor Rubric asks board again to hold general meeting, nominate directors
Sep 14Mereo BioPharma Group regains compliance with Nasdaq's listing rule
Jul 05Mereo BioPharma: Activist Pressure In A Net-Net Biopharma
Jun 17Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development
Dec 08Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
Apr 30Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$26m |
| Dec 31 2023 | US$2m | US$565k | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$32m |
| Mar 31 2023 | n/a | n/a | -US$42m |
| Dec 31 2022 | US$2m | US$507k | -US$42m |
| Sep 30 2022 | n/a | n/a | -US$31m |
| Jun 30 2022 | n/a | n/a | -US$23m |
| Mar 31 2022 | n/a | n/a | -US$4m |
| Dec 31 2021 | US$2m | US$539k | US$17m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | -US$37m |
| Mar 31 2021 | n/a | n/a | -US$131m |
| Dec 31 2020 | US$1m | US$545k | -US$224m |
| Sep 30 2020 | n/a | n/a | -US$198m |
| Jun 30 2020 | n/a | n/a | -US$177m |
| Mar 31 2020 | n/a | n/a | -US$111m |
| Dec 31 2019 | US$2m | US$518k | -US$46m |
| Sep 30 2019 | n/a | n/a | -US$41m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$41m |
| Dec 31 2018 | US$957k | US$484k | -US$41m |
| Sep 30 2018 | n/a | n/a | -US$42m |
| Jun 30 2018 | n/a | n/a | -US$44m |
| Mar 31 2018 | n/a | n/a | -US$50m |
| Dec 31 2017 | US$907k | US$493k | -US$52m |
Compensazione vs Mercato: Denise's total compensation ($USD2.22M) is below average for companies of similar size in the US market ($USD3.24M).
Compensazione vs guadagni: Denise's compensation has been consistent with company performance over the past year.
AMMINISTRATORE DELEGATO
Denise Scots-Knight (65 yo)
9.3yrs
Mandato
US$2,219,323
Compensazione
Dr. Denise Vera Scots-Knight, Ph.D. serves as President of OncoMed Pharmaceuticals, Inc. She serves as Director at Elanco Animal Health Incorporated since March 13, 2019. She co-founded Mereo BioPharma Gro...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 9.3yrs | US$2.22m | 1.92% $ 12.6m | |
| Co-Founder | 9.5yrs | US$1.09m | 0.58% $ 3.8m | |
| Chief Financial Officer | 3.8yrs | US$1.00m | 0.27% $ 1.8m | |
| Co-Founder & Chief Business Officer | 9.8yrs | Nessun dato | Nessun dato | |
| Chief Scientific Officer | 4.3yrs | Nessun dato | 0.060% $ 397.3k | |
| Senior VP & Therapeutic Head | no data | Nessun dato | Nessun dato | |
| Chief of Patient Access & Commercial Planning | 6.7yrs | Nessun dato | 0.033% $ 216.0k | |
| Senior Vice President of Clinical Development | 3.9yrs | Nessun dato | Nessun dato | |
| Senior VP and Head of Pharmaceutical Development & CMC | no data | Nessun dato | Nessun dato |
6.7yrs
Durata media
62yo
Età media
Gestione esperta: MREO's management team is seasoned and experienced (6.7 years average tenure).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Co-Founder | 9.7yrs | US$2.22m | 1.92% $ 12.6m | |
| Independent Non-Executive Chairman of The Board | 5.6yrs | US$156.80k | 0.016% $ 107.2k | |
| Independent Non-Executive Director | 5.6yrs | US$113.76k | 0% $ 0 | |
| Independent Non-Executive Director | 9.3yrs | US$121.31k | 0.17% $ 1.1m | |
| Independent Director | 2yrs | US$94.49k | 0.049% $ 322.8k | |
| Independent Director | 2yrs | US$100.96k | 0.049% $ 322.8k | |
| Independent Non Executive Director | 4.1yrs | US$105.08k | 0.0082% $ 53.7k | |
| Independent Director | 2yrs | US$97.75k | 0.049% $ 322.8k | |
| Independent Director | 3.2yrs | US$102.18k | 0.10% $ 661.9k | |
| Independent Director | 2yrs | Nessun dato | Nessun dato |
3.6yrs
Durata media
59yo
Età media
Consiglio di amministrazione esperto: MREO's board of directors are considered experienced (3.6 years average tenure).